CEO Ola Sandborgh comments: “Time flies and suddenly autumn is here. But as you know, time flies when you have a lot to do and at the same time having fun. Because that's how it is working at Lipum, days are full of activity and goal after goal is achieved. What feels most stimulating and exciting today is that we are approaching the end of the clinical phase 1 study when the last patient has been recruited and only a 90-day follow-up period remains before we can break the code and initiate the final report. With that, we will be able to take part of all the results, which will be in the beginning of 2025 when all analyses and compilations have been completed”

Financial summary July – September 2024

• Other operating income: KSEK 109 (51)
• Result after financial items: KSEK -1 680 (-6 605)
• Cash and cash equivalents as of September 30: KSEK 12 873 (17 551)

Significant events during the period July – September 2024

• Lipum AB (publ) recruits Peter Hovstadius as the new Chief Medical Officer (CMO).
• Lipum reports that the last patient has been enrolled in the ongoing phase 1 study with SOL-116.
• Lipum has received a preliminary report regarding the audit of the Horizon 2020 project.

Significant events after the period

• No significant events to report.

CEO Ola Sandborgh comments on the report in a live webcast on October 25 at 10:00 LINK.

The complete report (only in Swedish) is available at www.lipum.se.